Mechanism of the cardioprotective effects of @entity1205 pre-administration against XXXX -induced @entity1370 .

@entity632 @entity8 @entity137 @entity1205 @entity1431 @entity1370 @entity4420
We revealed that pre-treatment with @entity1205 ( @entity4420 ) 12 h before @entity632 (ADR) administration significantly reduced ADR-induced @entity137 compared with the simultaneous dosing schedule that was commonly used in previous studies. We considered that pre-treatment with @entity4420 relieves ADR-induced @entity1370 . In this study, we investigated the influence of @entity4420 on the pharmacokinetics and pharmacodynamics of ADR in order to clarify the mechanism by which @entity4420 pre-treatment relieves ADR-induced @entity1370 . When ADR and/or @entity4420 was intravenously administered, the @entity4420 pre-treatment ( @entity4420 -ADR) group showed significantly less @entity137 than the ADR-alone group. We examined hepatopathy, @entity8 , @entity1431 , and @entity1370 , all of which can cause @entity137 . Of these @entity137 , ADR-induced @entity1370 was significantly relieved in the @entity4420 -ADR group. To elucidate the mechanism by which @entity4420 pre-treatment relieved ADR-induced @entity1370 , lipid peroxidation as a proxy for the free radical level and the pharmacokinetics of ADR were measured. There was no difference in the pharmacokinetics of ADR between the ADR and @entity4420 -ADR groups. On the other hand, the @entity4420 -ADR group showed significantly inhibited lipid peroxidation in the heart compared with the ADR group. It was considered that @entity4420 pre-administration inhibited ADR-induced free radicals and decreased @entity1370 .
